EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Prognosis value of galectin-3 in patients with dilated cardiomyopathy: a meta-analysis

Yan Xiong, Qing Zhang

PeerJ · 2024

DOI: 10.7717/peerj.17201 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PeerJ, 2024. Verfasst von Yan Xiong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated, Galectin 3, Biomarkers, Galectins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accurate prediction and assessment of myocardial fibrosis (MF) and adverse cardiovascular events (MACEs) are crucial in patients with dilated cardiomyopathy (DCM). Several studies indicate that galectin-3 (gal-3) as a promising prognostic predictor in patients with DCM.

Methods

A comprehensive search was conducted in PubMed, EMBASE, the Cochrane Library, and Web of Science for relevant studies up to August 2023. The hazard ratios (HRs) of gal-3 for MACEs in DCM patients, and for MACEs in LGE(+) versus LGE(-) groups, were evaluated. Statistical analysis was performed using STATA SE 14.0 software.

Results

Seven studies, encompassing 945 patients, met the eligibility criteria. In DCM patients, abnormally elevated gal-3 levels were indicative of an increased MACEs risk (HR = 1.10, 95% CI [1.00–1.21], I 2 = 65.7%, p = 0.008). Compared with the LGE(-) group, the level of gal-3 in LGE(+) group was higher (HR = 1.12, 95% CI [1.05–1.19], I 2 = 31.4%, p = 0.233), and the combination of gal-3 and LGE significantly improved the prediction of MACEs. Sensitivity analysis confirmed the robustness of all results.

Conclusions

This study’s findings suggest that elevated gal-3 levels significantly correlate with increased MACE risk in DCM, highlighting its potential as a biomarker. However, significant heterogeneity among studies necessitates further research to ascertain gal-3’s predictive and diagnostic value in DCM prognosis, particularly in conjunction with LGE. PROSPERO ID CRD42023471199.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, DilatedGalectin 3BiomarkersGalectinsHumansPrognosisBlood ProteinsFibrosisMyocardium

Stichwörter der Autor:innen

CardiologyGalectin-3, dilated cardiomyopathies, MACEs, meta-analysisGenetics

Substanzen

Galectin 3BiomarkersLGALS3 protein, humanGalectinsBlood Proteins

Autor:innen und Institutionen

  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Cardiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Zitieren

APA

Xiong, Y., & Zhang, Q. (2024). Prognosis value of galectin-3 in patients with dilated cardiomyopathy: a meta-analysis. PeerJ. https://doi.org/10.7717/peerj.17201

Vancouver

Xiong Y, Zhang Q. Prognosis value of galectin-3 in patients with dilated cardiomyopathy: a meta-analysis. PeerJ. 2024. doi:10.7717/peerj.17201

BibTeX
@article{Xiong2024,
  author = {Xiong, Yan and Zhang, Qing},
  title = {Prognosis value of galectin-3 in patients with dilated cardiomyopathy: a meta-analysis},
  journal = {PeerJ},
  year = {2024},
  doi = {10.7717/peerj.17201}
}
Kostenlos starten →